At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 334 enrolled
Drug / intervention
MK-6213 +3 moredrug
Likely dose
Placebo for MK-6312 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy, and Tolerability of MK-6213 Co-Administered With Atorvastatin in Patients With Primary Hypercholesterolemia
In Brief
A Phase 2 clinical trial evaluating MK-6213, Atorvastatin calcium, and 2 other interventions for Hypercholesterolemia. Completed, enrolled 334 participants.
Detailed Summary
The purpose of this study is to test the safety and effectiveness of MK-6213 as compared to MK-6213/Atorvastatin in participants 18 to 75 years) with high cholesterol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartJun 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedMay 30, 2008
Enrollment StartJun 14, 2008
Primary CompletionJan 8, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.1 years ago
Interventions
MK-6213drug
MK-6213 160 mg for 4 weeks.
Atorvastatin calciumdrug
atorvastatin calcium 20mg for 4 weeks.
Placebo for MK-6312 160 mgdrug
Placebo for Atorvastatin 20 mgdrug